MedPath

Psychiatry of Transition in a World in Transition

Not Applicable
Recruiting
Conditions
Mental Disorder in Adolescence
Transitional Care
Mental Health
Interventions
Other: Risk and Protective Factors Assessment
Registration Number
NCT04333797
Lead Sponsor
Queen Fabiola Children's University Hospital
Brief Summary

This clinical study evaluates risk and protective factor to develop psychopathology in transitional age youth. 300 patients will be recruited at the age of 17 years old and assessed at baseline and 2 years later.

Detailed Description

Emerging adults are a particularly at-risk population in mental health. Transitional age youth have specific needs, not currently covered between child and adolescent mental health services (CAMHS) and adult mental health services (AMHS), mainly because of existing barriers. Movements from one to the other must be planned to achieve optimal patient care.

Our project aims to identify clinical dimensional characteristics contributing to the development of psychopathology during the transition period. Continuities, discontinuities and resilience factors will be explored. The final purpose is to develop a non-stigmatizing approach to reduce rejection from youths in psychopathological suffering and increase social inclusion.

The transversal and trans-diagnostic approach consists of a dimensional evaluation: 300 youth at the age of 17 will be included in a cohort of in-patients, out-patients and control group. Participants will be assessed at baseline and 2 years later. The primary outcome is based on Health of the Nation Outcome Scale for Children and Adolescents, measuring mental health care need, and WHO Quality of Life assessment.

The secondary outcomes include the assessment of dimensions representing risk or protective factors to develop psychopathology and evolution of mental health status during transition age. Baseline evaluation consists in internalizing/externalizing symptoms, impulsivity/compulsivity, emotion regulation, cognitive functioning, social and family functioning, developmental, medical and trauma history. At follow-up, mental health pathways and transition results will be described.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
300
Inclusion Criteria
  • French-speaking and French-understanding
  • Subjects who accepted to participated to the study (signature of informed consent/assent document from subjects and parents or legal holder of parental authority)
  • Specific criteria for patients: inpatients and out-patients
  • Specific criteria for control group: youth from general population or placed in residential centres
Exclusion Criteria
  • Impossibility to answer to the assessment tools
  • Medium intellectual disability (homogenous IQ < 75)
  • Presence of a grave somatic disease (cancer, cardiac failure, renal failure, central nervous system disorder), that is progressive or that affects the vital prognosis in the short term
  • Active participation to another study

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Transitional age youthRisk and Protective Factors AssessmentAssessed group.
Primary Outcome Measures
NameTimeMethod
Change from Baseline self-rated measure of quality of life at 2 yearsChange from Baseline WHO-QoL before transition at 17 y.o. to after transition at 19 y.o

Measured at baseline (T0) and follow-up (T1) with the Quality of life assessed by World Health Organisation Quality of Life Assessment (WHO-QoL-BREF)

Change from Baseline self-rated mental health status (need for care) at 2 yearsChange from Baseline HoNOSCA before transition at 17 y.o. to after transition at 19 y.o.

Measured at baseline (T0) and follow-up (T1) with the Health of the Nation Outcome Scale for Children and Adolescents (HoNOSCA).

Secondary Outcome Measures
NameTimeMethod
Executive functions assessment - alertness, divided attention, flexibility and working memoryBefore transition at 17 y.o. (T0)

Measured with Test of Attentional Performance (TAP)

Executive functions assessment - cognitive inhibitionBefore transition at 17 y.o. (T0)

Measured with STROOP Task

Self-rated measure of traumatic life eventsBefore transition at 17 y.o. (T0)

Measured with Childhood Trauma Questionnaire (CTQ)

Self-rated measure of family functioningBefore transition at 17 y.o. (T0)

Measured with Family Assessment Device (FAD)

Self-rated measure of internalising and externalising symptomsBefore transition at 17 y.o. (T0)

Measured with Youth Self Report 11-18 (YSR)

Self-rated measure of emotional regulationBefore transition at 17 y.o. (T0)

Measured with Emotion Regulation Questionnaire for Children and Adolescents (ERQ-CA)

Self-rated measure to quantify the risk of developing psychiatric disordersBefore transition at 17 y.o. (T0)

Measured with General Health Questionnaire (GHQ-12)

Self-rated measure of impulsivity and compulsivityBefore transition at 17 y.o. (T0)

Measured with Barratt Impulsiveness Scale (BIS-11)

Self-rated measure of depressivityBefore transition at 17 y.o. (T0)

Measured with Beck Depression Inventory-II (BDI-II)

Self-rated measure of suicidal riskBefore transition at 17 y.o. (T0)

Measured with Beck Scale of Suicide Ideation (BSS)

Self-rated measure of interpersonal relationships social adaptationBefore transition at 17 y.o. (T0)

Measured with Social Adaptation Self-evaluation Scale (SASS)

Self-rated measure of cognitive insightBefore transition at 17 y.o. (T0)

Measured with Beck Cognitive Insight Scale (BCIS)

Cognitive assessment - IQBefore transition at 17 y.o. (T0)

Measured with Wechsler Adult Intelligence Scale (WAIS-IV)

Executive functions assessment - planning taskBefore transition at 17 y.o. (T0)

Measured with Tower of London Test (TOL)

Self-rated measure of executive functionsBefore transition at 17 y.o. (T0)

Measured with Behavior Rating Inventory of Executive Function - Self report (BRIEF-SR)

Self-rated measure of therapeutic allianceAfter transition at 19 y.o. (T1)

Measured with Helping Alliance Questionnaire (HAQ)

Self-rated measure of transition related outcomesAfter transition at 19 y.o. (T1)

Measured with Transition Related Outcomes Mesure (TROM)

Self-rated measure of transition readiness and appropriatenessBefore transition at 17 y.o. (T0)

Measured with Transition Readiness and Appropriateness Mesure (TRAM)

Trial Locations

Locations (4)

Brugmann University Hospital

🇧🇪

Brussels, Belgium

Service santé mentale à l'ULB

🇧🇪

Brussels, Belgium

Erasme University Hospital

🇧🇪

Brussels, Belgium

Hôpital Universitaire Des Enfants Reine Fabiola

🇧🇪

Brussels, Belgium

© Copyright 2025. All Rights Reserved by MedPath